CN115779000A

CN115779000A - Coenzyme Q10 composition for preventing and treating osteoarthritis

Info

Publication number: CN115779000A
Application number: CN202211656876.2A
Authority: CN
Inventors: 吴铁; 林瑞; 唐林志; 崔燎; 吕思敏; 陆露娇; 王佳佳; 石爱云
Original assignee: Guangdong Runhe Biotechnology Co ltd
Current assignee: Guangdong Runhe Biotechnology Co ltd
Priority date: 2022-12-22
Filing date: 2022-12-22
Publication date: 2023-03-14
Anticipated expiration: 2042-12-22
Also published as: CN115779000B

Abstract

The invention discloses a coenzyme Q10 composition for preventing and treating osteoarthritis, and belongs to the field of medical technology extraction. The composition comprises coenzyme Q10, walnut oil, evening primrose oil, linseed oil and vitamin E. According to the invention, through compounding coenzyme Q10 with various oils and fats and vitamin E, the oils and fats can completely dissolve the coenzyme Q10 and keep the stability of the oils and fats; meanwhile, the invention discovers that the specifically selected grease can have the effect of promoting the cartilage protection and cartilage generation promotion of the coenzyme Q10.

Description

Coenzyme Q10 composition for preventing and treating osteoarthritis

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to a coenzyme Q10 composition for preventing and treating osteoarthritis.

Background

Osteoarthritis (OA) is a disease characterized significantly by cartilage damage, synovial inflammation, and subchondral bone remodeling, with incidence positively correlated with age; the cartilage damage is the initiation link throughout the course of OA. Osteoarthritis is one of the main causes of disability in the middle-aged and elderly people due to the difficulty in repair after cartilage damage. To date, approximately 3 hundred million people worldwide have osteoarthritis, with a morbidity of 49.1% to 51.3% in people older than 50 years of age, and with the ongoing progress of OA, the ultimate disability rate of 52.5% to 53.6%. Currently, OA of osteoarthritis worldwide is associated with substantial economic costs estimated in developed countries, accounting for 1% to 2.5% of GDP, most of which (85%) are due to the expense of joint replacement surgery.

OA is a disease of the entire joint, with pathological changes occurring in the bones, including the synovial membrane, meniscus and ligaments, and with major symptoms including pain, stiffness and loss of function. The etiology of OA is intricate, involving genetics, obesity, smoking, estrogen levels, mechanical stress and local trauma, etc., and there is an inconsistency between the presence of symptoms and changes in imaging, with many people with imaging OA (up to 50%) not having associated symptoms. The reason for this apparent discrepancy is not clear, probably because X-ray plain is an insensitive indicator of structural and nociceptive changes that occur in OA.

In view of the complex and varied pathogenesis and unpredictable nature of OA, OA is becoming a serious disease threatening human life safety and placing a great economic burden on society. Current treatments for OA are primarily via drug pain relief and conservative treatment via weight loss exercise, but there is no specific treatment. Therefore, further understanding the pathogenesis of OA, and developing appropriate therapeutic means in a targeted manner to find new therapeutic drugs are the urgent scientific problems to be solved at present.

In terms of surgical treatment, arthroscopic bone marrow stimulation debridement, autologous or allogeneic osteochondral transplantation, autologous chondrocyte transplantation, and autologous periosteal bone grafting have become routine methods for treating OA. Research shows that the arthroscopic BMS cleaning technique has the advantages of small wound, simple operation and the like, and can improve the clinical curative effect to a certain extent. However, the repaired cartilage is fibrocartilage, which is less wear resistant than normal cartilage. After a period of time, the long-term efficacy is still not ideal. Autologous chondrocyte transplantation (ACI) is suitable for the first treatment of large osteochondral defects left after failure. However, the method is long in time consumption, high in cost and inaccurate in clinical effect. Periosteum bone grafting is also suitable for patients with large osteochondrosis. The advantages are that the periosteum has a certain chondrogenesis capability, the periosteum of the bone graft is tightly combined with the bone, and the problem of layered repair between the cartilage and the subchondral bone is solved. However, the periosteal layer may be hyperproliferative, requiring secondary arthroscopic repair, increasing trauma from the surgery.

Antioxidants play an important mechanism of action in anti-inflammatory. Because oxidative stress can lead to an inflammatory response, antioxidants reduce inflammation and prevent the production of toxic oxidants. Antioxidants have been reported to inhibit inflammation. Coenzyme Q10 (CoQ 10), an oil-soluble substance, is present in cells in most eukaryotes. This enzyme reduces oxidative stress and is involved in oxidative phosphorylation pathways. Coenzyme Q10 is reportedly responsible for the attenuation of oxidative stress caused by injury. It is also well documented that an important role of coenzyme Q10 is the production of Adenosine Triphosphate (ATP), which is involved in the oxidative phosphorylation pathway mitochondria in vivo.

Because of the unavoidable side effects of traditional chemical drugs, stem cell biotherapy has not been popularized in clinic so far, surgical treatment cost is high, and the risk of postoperative sequelae exists, it is important to find a treatment method for OA in natural products and their derivative compounds. In the field of OA treatment, the search for natural products has never been stopped, and their therapeutic value in bone health is attributed to their chondroprotective and osteoprotective properties. Many of these natural products are reported to have anti-inflammatory and antioxidant properties, anti-catabolic effects on chondrocytes, and inhibitory effects on osteoclast differentiation. Various natural products exhibit similar mechanistic properties to chondrocytes, such as anti-inflammatory and antioxidant effects, inhibition of the NF- κ B signaling pathway, and inhibition of catabolic activity of MMPs. In addition to the chondroprotective effect, the natural products also showed a bone protective effect, up-regulating the expression of various factors (e.g., runx2, OPN and Osx) in addition to the up-regulation of the ratio OPG/RANKL. These modulations reduce bone resorption, enhance osteoblast activity, and down-regulate osteoclast activity. Therefore, the natural product and the derivative compound thereof have great potential for treating OA, and can be used as a potential substitute for conventional therapy because the natural product and the derivative compound thereof have no obvious toxic or side effect, are simple and convenient to take daily and are low in price. Furthermore, due to the wide and varied sources of natural products and their derivative compounds, it would be desirable to optimize the formulation of natural products or to adjust their combinations to combat and prevent OA.

CN105456049A discloses a coenzyme Q10 massage cream with anti-inflammatory, analgesic and skin-care functions; the external application form is combined with physical therapy, and coenzyme Q10 is applied to the analgesic effect of the arthritis; but because the coenzyme Q10 has larger molecular weight and is a fat-soluble component, the percutaneous absorption efficiency is preferred; while only the analgesic effect is mentioned, the effect of the specific analgesic effect is not tested; nor whether or not arthritis can be inhibited or treated has been specifically investigated.

Disclosure of Invention

The invention provides a coenzyme Q10 composition for preventing and treating osteoarthritis, which can protect cartilage, reduce cartilage abrasion and promote chondrogenesis.

In order to achieve the purpose, the invention adopts the following technical scheme:

a coenzyme Q10 composition for preventing and treating osteoarthritis comprises the following components in parts by mass:

in particular, medically acceptable auxiliary materials and carriers are also included.

In particular, the medically acceptable auxiliary material comprises at least one of gelatin, water, glycerin, beeswax, an opacifier and a colorant.

Particularly, the coenzyme Q10 composition for preventing and treating osteoarthritis is a soft capsule.

The invention also protects the application of the composition in preparing a medicament for treating or preventing arthritis.

Coenzyme Q10 is a fat-soluble antioxidant, can activate the nutrition of human cells and cell energy, has the functions of improving the immunity of human bodies, enhancing the antioxidation, delaying the senility, enhancing the activity of human bodies and the like, is widely used for cardiovascular system diseases in medicine, and is widely used for nutritional health care products and food additives at home and abroad. The invention finds that inflammation and arthritis can be inhibited; inducing anti-inflammatory reaction, resisting arthritis and resisting oxidation.

The walnut oil, the evening primrose oil and the linseed oil are edible oil and are non-toxic to human bodies; coenzyme Q10 was dissolved in the solvent. Meanwhile, the invention discovers that the compounding of the walnut oil, the evening primrose oil and the linseed oil can enhance the effect of the coenzyme Q10 compared with other nontoxic edible oils.

Vitamin E acts as a fat-soluble antioxidant and enhances the effect of coenzyme Q10.

The invention also comprises medically acceptable auxiliary materials, including gelatin, purified water and glycerol for preparing capsule shell auxiliary materials; emulsifier beeswax; opacifier titanium dioxide; the coloring agents lemon yellow and allure red, etc.

The present invention is generally directed to products in the form of soft capsules prepared by methods conventional in the art.

Compared with the prior art, the invention has the beneficial effects that:

(1) The invention discovers that the anti-inflammatory and antioxidant effects of coenzyme Q10 can protect cartilage, thereby reducing cartilage abrasion; meanwhile, coenzyme Q10 has the function of promoting chondrogenesis. Can be used for preventing or treating osteoarthritis effectively.

(2) According to the invention, through compounding coenzyme Q10 with various oils and fats and vitamin E, the oils and fats can completely dissolve the coenzyme Q10 and keep the stability of the oils and fats; meanwhile, the invention discovers that the specifically selected grease can have the effect of promoting the cartilage protection and cartilage generation promotion of the coenzyme Q10. Vitamin E also has antioxidant effect, and can act together with coenzyme Q10.

Drawings

FIG. 1 is a graph showing the change in body weight of rats in each group during continuous 8-week gavage treatment according to the example of the present invention.

FIG. 2 shows the effect of Q10 on the general knee joint of the OA model in SD rats.

FIG. 3 is a graph of the effect of Q10 on bone damage to the medial femoral condyle of the knee joint and the subchondral bone of the medial tibial plateau of the OA model of SD rats.

FIG. 4 is a graph of the effect of Q10 on the medial tibial plateau subchondral bone of the SD rat OA model surgery.

FIG. 5 shows the effect of Q10 on OA model in SD rats on knee joint hyperosteogeny and cartilage abrasion at the operative side.

Fig. 6 quantifies the degree of degradation, average thickness, and total area of cartilage on the medial surgical tibial plateau surface.

FIG. 7 is a flow chart of the present invention rat medial meniscal-tibial ligament resection (DMM).

Fig. 8-1, 8-2, and 8-3 show the quantitative results after the scale-up test.

Detailed Description

For a better understanding of the present invention, the present invention is further described in conjunction with the following specific examples, wherein the terminology used in the examples is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention.

In the invention:

coenzyme Q10 is an oxidative coenzyme Q10, ubiquinone.

The oleum Juglandis is oil squeezed from kernel of Juglans regia L.

The oleum Oenotherae Erythrosepalae is oil squeezed from mature seed of Oenothera biennis L.

The linseed oil is oil squeezed from mature seed of Linum usitatum L.

1 construction of OA model of SD rat

Osteoarthritis (OA) is the most common form of arthritis and is also the leading cause of pain and disability. Common risk factors for OA of the knee joint include age, sex, obesity, past joint injury and mechanical factors, as well as joint misalignment and arthrokinematic abnormalities during walking. Although knee joint OA is multifactorial in nature, the mechanical environment of the knee joint during walking has a profound effect on the initiation and progression of knee joint OA. Menisci play an important role in the weight bearing distribution of the knee joint. The loss of meniscal function, either through dissociation or partial removal of the meniscus, is accompanied by an increase in the mechanical load on the cartilage and subchondral bone of the affected knee, ultimately leading to OA conditions. A total meniscectomy would increase the risk of OA in the knee joint 14-fold even more after 21 years. Therefore, a rat OA model was constructed by surgery for medial meniscal instability (DMM), and has been used for basic studies of common knee joint OA.

30 male SD rats were randomly divided into the following 3 groups (10 per group) according to body weight interval: sham group (left joint posterior suture exposed, not given to surgery), OA group, Q10 group: (after exposure of the right side joint, surgical molding, free medial meniscus). The rats were anesthetized by intraperitoneal injection with 2% pentobarbital sodium at a dose of 0.13ml/100g, the right knee joint of the rats was dissected longitudinally, and the knee joint meniscus dissociation surgery was performed to establish a rat OA model. The specific surgical procedure is shown in fig. 7: (A) The right knee joint of SD rats was exposed until the medial meniscus appeared; (B) exposing the collateral ligament of the right knee joint of SD rats; (C) using an ophthalmic scissors to cut off the collateral ligaments; (D) confirming complete shearing of the collateral ligament; (E) Inserting an ophthalmic scissors into the medial meniscus and medial femoral condyle and cutting a knife; (F) An ophthalmic scissors is inserted into the medial meniscus and tibial plateau and a knife is cut. After the 6 steps are completed, slightly poking the inner meniscus by using an ophthalmic scissors, and if the inner meniscus is loosened, indicating that the inner meniscus is in a free state, and finishing the operation; if the medial meniscus remains stable, repeating steps (E) and (F) until the medial meniscus is loose. The SD rat is sutured with the wound surface after model building, and is injected with sodium penicillin in the abdominal cavity to resist infection.

After operation, each group of rats is subjected to intragastric administration treatment according to groups, the intragastric administration is carried out for 1 time every day, and the materials are taken after continuous administration for 8 weeks. Animal dosing groups and doses are shown in table 1.

TABLE 1 animal dosing groups and dosages

In Table 1, the composition of coenzyme Q10 is as follows (wt%):

the beeswax, the gelatin and the water are only used as components for adjusting concentration, have no effect and do not influence experimental results.

2SD rat knee joint general structure analysis

The general knee joints of SD rats were observed using a stereomicroscope and operated as follows: collecting SD rat hind limb specimen, removing residual muscle connected with femur and tibia periphery, longitudinally cutting rat right side knee joint, removing patella and retaining joint capsule, and taking under stereomicroscope. The rat osteoarthritis lesion area measurement histopathology scoring criteria were subsequently used to quantify the scoring.

3SD rat knee joint bone tissue plane structure analysis

The general knee joint observation of SD rats by an X-ray scanner was performed as follows: the upper femoral and lower tibial segments of the rat knee were generally sawn off using a slow saw, leaving a knee sample of approximately 2cm in length and placed in an X-ray scanner for scanning. X-ray scanning parameters: 40kv,3.40s,0.20mA.

4SD rat knee joint bone tissue microstructure analysis

The bone microstructure of SD rats was examined using Micro-computerized Tomography (Micro CT) as follows: the SD rat knee joint sample is placed inside a Micro CT instrument for scanning. Viva CT80 selects the scan parameters: scanning was performed by selecting high resolution (image matrix: 2048X2048, integration time: 200ms; energy/intensity: 70kVP, 114. Mu.A, 8W, voxelsize 15.6. Mu.m), 1200mgHA/cm as a corrected CT value. After the scan is completed, the fracture position is corrected by using DataViewer software. A Region Of Interest (ROI) was selected and bone tissue images were quantitatively analyzed using the CTAn program in Skyscan software. The following parameters were measured and calculated: the Number of osteophytes (Number of osteophytes), the IOD value for femoral injuries (IOD of femur dam), and the IOD value for tibial plateau injuries (IOD of tibial plateau dam). The three-dimensional structure of bone tissue was observed in Skyscan using the CTvox program.

5SD rat knee joint bone histopathological analysis

After Micro-CT scanning is completed on rat femurs, the rat femurs are soaked in 12% EDTA decalcification solution, after decalcification is carried out for 6 weeks at room temperature, the specimens are observed to be semitransparent visually, a needle is inserted into hard bone tissues to have no gritty feeling, then gradient dehydration and transparency are carried out according to experimental requirements, and the specimens are soaked in wax in the sequence of soft wax for 2h and hard wax for 2h, and finally paraffin embedding is carried out, and the specimens are sliced into sections of 4 mu m.

(1) Paraffin section deparaffinization to hydration:

paraffin section → 60 ℃ baking 2h → xylene dewaxing 2 times (15 min/time) → gradient ethanol hydration (100% → 100% → 95% → 85% → 75% → pure water) for 2min of each treatment.

(2) Toluidine blue staining: (1) dewaxing and hydrating conventionally; (2) dripping 0.1% toluidine blue dye solution on the tissue, and dyeing for 1-2 min; (3) washing with tap water for 1min; (4) washing with distilled water for 1min; (5) conventional rehydration, and xylene transparency for 2 times, 2 min/time; (6) the gel was mounted on a neutral resin, observed under a microscope and photographed.

(3) H & E staining: (1) dewaxing and hydrating conventionally; (2) dropping and dyeing hematoxylin for 5min, and washing with running water for 1min; (3) differentiating with 1% ethanol hydrochloride differentiation solution for 2s, and washing with running water for 1min; (4) dyeing with eosin drop for 1min, and washing with running water for 1min; (5) after natural air drying, the gum is sealed, observed under a microscope and photographed.

6 statistical method

Data were analyzed using SPSS19.0 statistical software, statistical differences between Sham surgery group (Sham) and osteoarthritis model group (OA) were tested using independent sample t; statistical differences between the osteoarthritis model group (OA) and the drug treatment group (Q10) were each determined by One-way ANOVA, fisher Left Significant Difference (LSD) for homogeneity of variance, and Tamhane' sT2 (M) for pairwise comparison for non-homogeneity of variance. P <0.05 indicates that the difference is statistically significant. The analysis was plotted using GraphPad Prism 8.0 software.

7 results of the experiment

7.1Q10 Effect on OA model body weight in SD rats

As shown in FIG. 1, the weight data of the rats were recorded once a week during the gavage treatment, and the weight of each group of rats showed a tendency to increase steadily with time. There was no significant difference in body weight between the groups over the 8 week period of the gavage treatment.

7.2Q10 Effect on the general of the surgical side Knee in the OA model in SD rats

As shown in panel a of fig. 2, the study successfully constructed a SD rat knee osteoarthritis model through medial meniscus instability. The general results of the joint showed that, compared with Sham group, the cartilage on the surface of medial femoral condyle of rats in OA group was worn out, the subchondral bone of medial femoral condyle was directly exposed, and the subchondral bone was damaged and hardened. The general results of joint treatment with gastric lavage coenzyme Q10 drug after DMM operative modeling show that the cartilage and subchondral bone on the surface of femoral condyle of rats in the coenzyme Q10 group are improved to different degrees compared with the OA group. Pathological scoring was performed on the knee joints of rats in each group in general according to the rat osteoarthritis pathological scoring system, and the results are shown in fig. 2C.

As shown in the B-chart of FIG. 2, when the control was performed by only gavage saline after DMM surgery, the X-ray planar scan showed that the gap between the knee joints of the rats in the OA group was narrowed compared with that in the Sham group. The pharmacological treatment of the gavage coenzyme Q10 after the DMM operation modeling, and the X-ray plane scanning result shows that compared with the OA group, the pathological phenomenon that the knee joint gap of the rat in the coenzyme Q10 group is narrowed is improved.

7.3 Effect of Q10 on OA model in SD rat surgical side Knee Joint bone injury and bone sclerosis

(1) Influence of Q10 on bone injury of medial condyle of femur and subchondral bone of medial tibial plateau of knee joint in OA model operation of SD rat

As shown in panel a of fig. 3, the present study successfully constructed an SD rat knee osteoarthritis model by medial meniscus instability. After the DMM operation molding, only the stomach saline is perfused for comparison, and Micro CT results show that, compared with the Sham group, the rats in the OA group have femoral condyle damage phenomena, the bone damage of the medial condyle is particularly obvious, and compensatory hyperosteogeny at two sides of the femoral condyle is serious, so that the bone surface is uneven. After the DMM operation molding, the Micro CT result shows that the damage phenomenon of the femoral condyle of a rat of the coenzyme Q10 group is improved compared with the OA group, and the rat is mainly characterized in that the femoral condyle has no large-area bone damage, the patellar surface is smooth, and the two sides of the femoral condyle have no large-area compensatory hyperosteogeny.

As shown in E and F of FIG. 3, after the DMM operation, the contrast was performed only by gavage of normal saline, and the Micro CT results showed that the medial subchondral bone of the medial tibial plateau of the OA group rats had significant bone damage compared with the Sham group, and the bone surface damage was located in the medial posterior region of the medial subchondral bone of the medial tibial plateau. After the DMM operation model building, the Micro CT result shows that the bone damage phenomenon of the subchondral bone of the medial tibial plateau of the rat of the coenzyme Q10 group is improved and is represented as smooth bone surface of the subchondral bone of the medial tibial plateau by Micro CT result compared with the OA group.

The bone damage of medial femoral condyle and medial tibial plateau subchondral bone of each group of rats was quantitatively analyzed by Integrated Optical Density (IOD), and the amount of compensatory hyperosteogeny on both sides of femoral condyle of each group of rats was counted, and the results are shown in B, C and D of fig. 3.

(2) Influence of Q10 on medial tibial plateau subchondral bone of OA model of SD rat

As shown in fig. 4, the study successfully constructed a SD rat knee osteoarthritis model through medial meniscus instability. Because the medial meniscus is unstable, the biological stress borne by the subchondral bone of the medial tibial plateau is also increased and the stress distribution is uneven. Therefore, the study delineated the medial tibial plateau subchondral bone from front to back into 5 areas of ABCDE, respectively, and performed a cross-sectional analysis of trabecular bone of the medial tibial plateau subchondral bone of the 5 areas. After the DMM operation modeling, only the stomach physiological saline is perfused for contrast, and Micro CT results show that compared with the Sham group, the cartilage of the medial tibial plateau of the rats in the OA group shows bone absorption in the areas A and E; exhibits a sclerosing phenomenon in zones B and D; the bone damage phenomenon is shown in the C area. After the DMM operation model building, the coenzyme Q10 medicine treatment is performed by intragastric administration, and Micro CT results show that compared with an OA group, the pathological changes of the subchondral bone of the medial tibial plateau of a rat of the coenzyme Q10 group are relieved, and the pathological changes are represented as follows: bone resorption phenomena are exhibited in zones a and E; slight bone hardening phenomenon is shown in B area and D area; no bone damage occurred in zone C, but significant bone hardening occurred.

7.4Q10 effects on OA model surgical knee joint hyperosteogeny and cartilage abrasion in SD rats

As shown in fig. 5, the present study successfully constructed a SD rat knee osteoarthritis model through medial meniscus instability. After the DMM operation modeling, only the gastric saline is infused for comparison, and H & E and Toluidine blue staining results show that compared with the Sham group, the hyperosteogeny phenomenon appears in the medial epicondyle of the operation side femur of the rats in the OA group; the subchondral bone of the medial tibial plateau on the operation side tends to be thickened; severe cartilage degradation on the tibial plateau surface; the tide lines are blurred; cartilage thickness is greatly reduced; the cartilage area is greatly reduced; moreover, the chondrocytes are morphologically shrunken and their number is extremely rare. The H & E and Toluidine blue staining results show that the area of the intraoperative epicondyle hyperosteogeny of the operative side femur of rats in the coenzyme Q10 group is slightly reduced compared with the OA group; the subchondral bone of the medial tibial plateau on the operation side has a slight thickening tendency; the cartilage degradation on the surface of the tibial plateau is relieved; the tide lines are clearer; increased cartilage thickness; increased cartilage area; and the chondrocytes are full in shape and large in number.

The degree of degeneration, average thickness and total area of the cartilage on the surgical side medial tibial plateau surface of each group of rats were quantified using Image Pro Plus 6.0, and the results are shown in fig. 6.

8 conclusion

The results of this study show that SD rats have a steady increase in body mass at 8 weeks of DMM surgery, and the medial femoral condyle and the cartilage on the tibial plateau surface are almost completely consumed after 8 weeks of narrowing of the surgical knee joint space. Gross visual observation of the knee joint generally revealed large areas of subchondral bone exposure. Micro CT analysis indicated the presence of hardening and damage to subchondral bone. The results of histological section staining of knee joints showed that the OA rat model showed severe cartilage loss on the tibial plateau surface, and a shriveled chondrocyte morphology, which was in an apoptotic state. Meanwhile, in addition to bone and cartilage damage, the knee joint has joint capsule thickening and osteophyte hyperplasia, resulting in joint capsule swelling.

The Q10 intragastric therapy is carried out on an OA rat model for 8 weeks, and the results show that Q10 can relieve the pathological condition of narrowing of the knee joint on the operation side of the OA rat, and the cartilage of the medial femoral condyle and the tibial plateau surface of the OA rat is less lost and is relatively glossy. Gross visual observation of the knee joint, no subchondral bone was exposed. Micro CT analysis shows that the subchondral bone has a hardening phenomenon, but the subchondral bone is slightly damaged. The results of tissue section staining of the knee joint show that the cartilage on the surface of the tibial plateau of the rats in the group Q10 is restored to be close to the normal level, but the cartilage is still slightly lost, and the chondrocyte morphology of the rats is full. At the same time, osteophyte proliferation continues to exist and the osteophytes are bulky. The above results indicate that Q10 protects bone and cartilage in the OA rat model.

9 amplification experiment

An expansion experiment was conducted using the test methods of 1-7 above, except that the administration of the group gavage treatment was as shown in table 2 below:

TABLE 2 animal dosing groups and dosages

The degree of degeneration, average thickness and total area of the surgical medial tibial plateau surface cartilage of each group of rats were quantified using Image Pro Plus 6.0, and the results are shown in FIGS. 8-1, 8-2 and 8-3.

The above detailed description is specific to one possible embodiment of the present invention, and the embodiment is not intended to limit the scope of the present invention, and all equivalent implementations or modifications without departing from the scope of the present invention should be included in the technical scope of the present invention.

Claims

1. The coenzyme Q10 composition for preventing and treating osteoarthritis is characterized by comprising the following components in parts by mass:

2. the coenzyme Q10 composition for the prevention and treatment of osteoarthritis according to claim 1, further comprising pharmaceutically acceptable adjuvants and carriers.

3. The coenzyme Q10 composition for the prevention and treatment of osteoarthritis according to claim 1, wherein the pharmaceutically acceptable excipients comprise at least one of gelatin, water, glycerin, beeswax, an opacifier and a colorant.

4. The coenzyme Q10 composition for the prevention and treatment of osteoarthritis according to claim 1, wherein the composition is a soft capsule.

5. Use of a composition according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment or prevention of arthritis.